UMB Bank’s Mineralys Therapeutics MLYS Stock Holding History

UMB Bank’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,046	Closed	-$9.95K	–	1687
2023 Q3	$9.95K	Buy	+1,046	New	+$13.6K	﹤0.01%	1294

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UMB Bank's MLYS Position: Q4 2023 in Review

UMB Bank sold out of Mineralys Therapeutics (MLYS) in Q4 2023, closing a stake of 1,046 shares — an estimated $9.95K sold.

UMB Bank first reported a position in MLYS in Q3 2023 and held it in 1 quarter. The position peaked at $9.95K in Q3 2023. 87 funds tracked by Wall St. Rank hold MLYS as of Q4 2023.

UMB Bank reported no remaining Mineralys Therapeutics position as of Q4 2023 after selling out during the quarter.
UMB Bank sold 1,046 Mineralys Therapeutics shares in Q4 2023, an estimated $9.95K.
UMB Bank first reported a position in Mineralys Therapeutics in Q3 2023 and held it in 1 quarter.
UMB Bank's Mineralys Therapeutics position peaked at $9.95K in Q3 2023.
87 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2023.

Based on UMB Bank's 13F filing for Q4 2023, filed 23 Jan 2024.